Showing results (211-220 of 757) with videos related to

Sort By:
Pageof 76
Artificial Organs|April 23, 2015
Pharmacokinetics of Certoparin During In Vitro and In Vivo DialysisDetlef H Krieter, Susanne Fink, Oliver Dorsch, et al.
Nephron|August 22, 2021
Comparison of Static and Dynamic Baseline Creatinine Surrogates for Defining Acute Kidney InjuryDavid G Warnock, Javier A Neyra, Etienne Macedo, et al.
Diabetes, Obesity & Metabolism|September 24, 2021
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trialJoão Pedro Ferreira, Silvio E Inzucchi, Michaela Mattheus, et al.
Kidney International|October 10, 2002
Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage?Peter Stenvinkel, Christoph Wanner, Thomas Metzger, et al.
European Journal of Heart Failure|July 28, 2011
Homoarginine, heart failure, and sudden cardiac death in haemodialysis patientsChristiane Drechsler, Andreas Meinitzer, Stefan Pilz, et al.
Diabetes & Vascular Disease Research|December 14, 2020
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®Gisle Langslet, Bernard Zinman, Christoph Wanner, et al.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|May 22, 2012
Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonanceTheresa Reiter, Oliver Ritter, Martin R Prince, et al.
The New England Journal of Medicine|July 22, 2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisChristoph Wanner, Vera Krane, Winfried März, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 10, 2018
Prognostic Value of High-Sensitivity Versus Conventional Cardiac Troponin T Assays Among Patients With Type 2 Diabetes Mellitus Undergoing Maintenance HemodialysisTill Keller, Christoph Wanner, Vera Krane, et al.
BMJ Open|September 13, 2018
Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 studyHolger Reinecke, Sabine Jürgensmeyer, Christiane Engelbertz, et al.
Pageof 76